[Medications for diabetic macular edema].
Kitano
Shigehiko
S
Department of Ophthalmology, Diabetes Center, Tokyo Women's Medical University.
D000086:Acetazolamide / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D003941:Diagnostic Techniques, Ophthalmological; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use*; D015552:Injections, Intralesional; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008301:Maleimides / Q000494:pharmacology / Q000627:therapeutic use*; D011379:Prognosis; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D064546:Protein Kinase C beta; D011758:Pyrroles / Q000627:therapeutic use*; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D007211:Indoles; D008301:Maleimides; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; C116890:Semaxinib; C099154:ruboxistaurin; D011493:Protein Kinase C; D064546:Protein Kinase C beta; D014222:Triamcinolone Acetonide; D000086:Acetazolamide